Nuclear receptor subfamily 4 group A member 3 (NR4A3)

Nuclear receptor subfamily 4 group A member 3 (NR4A3), also known as neuron-derived orphan receptor 1 (NOR1), is an intracellular nuclear receptor and transcription factor. NR4A3 belongs to the NR4A receptor subfamily and is considered an orphan receptor because no endogenous ligand has been conclusively identified. NR4A3 is highly conserved and structurally similar to other NR4A family members (NR4A1/Nur77, NR4A2/Nurr1), having a DNA-binding domain and a ligand-binding domain. NR4A3 is expressed in multiple tissues including the brain, cardiovascular system, skeletal muscle, liver, pancreas, T lymphocytes, and tumor cells. Its expression is rapidly induced by physiological and pathological stimuli such as growth factors, stress, cytokines, neurotransmitters, and metabolic changes. NR4A3 regulates the transcription of genes governing cell proliferation, differentiation, apoptosis, metabolism, mitochondrial function, vascular remodeling, immune tolerance (especially T cell development and function), and is implicated in the development or progression of diseases such as atherosclerosis, heart failure, diabetes, cancer, and neurodegenerative disorders. Despite its potential as a therapeutic target, there are currently no selective modulators of NR4A3 in clinical use[1][2][3].

Other names

Neuron-derived orphan receptor 1 (NOR1)Mitogen-induced nuclear orphan receptorNuclear hormone receptor NOR-1CHNCSMFMINORTECTranslocated in extraskeletal chondrosarcoma

Ligand-independent transcription regulation by binding specific DNA response elements (monomer binding to NBRE, homodimer/heterodimer to Nur-Response Element); no evidence of drugs with established, specific mechanisms of pharmacological action via direct NR4A3 modulation in humans[1][3]